Retinoids activate the irritant receptor TRPV1 and produce sensory hypersensitivity

Journal of Clinical Investigation

Volumn 123, Issue 9, 2013, Pages 3941-3951

  Yin, Shijin ^a,b   Luo, Jialie ^a,c   Qian, Aihua ^a,d   Du, Junhui ^e   Yang, Qing ^a   Zhou, Shentai ^e   Yu, Weihua ^a,f   Du, Guangwei ^a   Clark, Richard B ^a   Walters, Edgar T ^a   Carlton, Susan M ^e   Hu, Hongzhen ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b SOUTH CENTRAL UNIVERSITY FOR NATIONALITIES   (China)

^c SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

^e University of Texas Medical Branch School of Medicine   (United States)

^f CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL)CARBOXAMIDO]BENZOIC ACID; 4 [2 [5,6 DIHYDRO 5,5 DIMETHYL 8 (4 METHYLPHENYL) 2 NAPHTHYL]ETHYNYL]BENZOIC ACID; ALITRETINOIN; BEXAROTENE; CAPSAICIN; ETRETIN; IONOTROPIC RECEPTOR; IRRITANT AGENT; ISOTRETINOIN; N (1,4 BENZODIOXAN 6 YL) 3 (4 TERT BUTYLPHENYL)ACRYLAMIDE; RETINOIC ACID; RETINOID; TAZAROTENE; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 1 ANTAGONIST; BENZOIC ACID DERIVATIVE; CALCITONIN GENE RELATED PEPTIDE; NICOTINIC ACID DERIVATIVE; RETINOIC ACID RECEPTOR; TETRALIN DERIVATIVE; TRPV1 PROTEIN, MOUSE; VANILLOID RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPERALGESIA; HYPERSENSITIVITY; INFLAMMATION; MOLECULAR MECHANICS; MOUSE; NEUROGENIC INFLAMMATION; NONHUMAN; PAIN; PAW EDEMA; PEPPER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; SKIN DISEASE; ACTION POTENTIAL; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; C57BL MOUSE; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; EDEMA; HEK293 CELL LINE; HINDLIMB; KNOCKOUT MOUSE; METABOLISM; NOCICEPTION; PAIN RECEPTOR; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SPINAL GANGLION;

ACITRETIN; ACTION POTENTIALS; ANIMALS; BENZOATES; BINDING SITES; CALCITONIN GENE-RELATED PEPTIDE; EDEMA; GANGLIA, SPINAL; HEK293 CELLS; HINDLIMB; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, MOLECULAR; NICOTINIC ACIDS; NOCICEPTION; NOCICEPTORS; RECEPTORS, RETINOIC ACID; RETINOIDS; SIGNAL TRANSDUCTION; TETRAHYDRONAPHTHALENES; TRPV CATION CHANNELS;

EID: 84883506574     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI66413     Document Type: Article

References (77)

1. Tanumihardjo SA. Vitamin A: biomarkers of nutrition for development. Am J Clin Nutr. 2011;94(2):658S-665S.
2. Tang XH, Gudas LJ. Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol. 2011;6:345-364.
3. Thacher SM, Vasudevan J, Chandraratna RA. Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des. 2000;6(1):25-58. (Pubitemid 30395460)
4. Hsu P, Litman GI, Brodell RT. Overview of the treatment of acne vulgaris with topical retinoids. Postgrad Med. 2011;123(3):153-161.
5. Geria AN, Lawson CN, Halder RM. Topical retinoids for pigmented skin. J Drugs Dermatol. 2011;10(5):483-489.
6. Yu W, Burns CM. All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis. J Clin Rheumatol. 2009;15(7):358-360.
7. Fiallo P, Tagliapietra AG. Severe acute myopathy induced by isotretinoin. Arch Dermatol. 1996;132(12):1521-1522. (Pubitemid 26424564)
8. Pehlivan Y, Kisacik B, Sayiner ZA, Onat AM. Inflammatory back pain in patients treated with isotretinoin. J Rheumatol. 2011;38(12):2690.
9. Leyden JJ, Grossman R, Nighland M. Cumulative irritation potential of topical retinoid formulations. J Drugs Dermatol. 2008;7(8 suppl):s14-s18.
10. Mukherjee S, Date A, Patravale V, Korting HC, Roeder A, Weindl G. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1(4):327-348.
11. Webster GF, Berson D, Stein LF, Fivenson DP, Tanghetti EA, Ling M. Efficacy and tolerability of oncedaily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis. 2001;67(6 suppl):4-9.
12. Leyden J, Grove GL. Randomized facial tolerability studies comparing gel formulations of retinoids used to treat acne vulgaris. Cutis. 2001;67(6 suppl):17-27.
13. Leyden JJ. Topical treatment of acne vulgaris: retinoids and cutaneous irritation. J Am Acad Dermatol. 1998;38(4):S1-S4. (Pubitemid 28182949)
14. Alique M, Lucio FJ, Herrero JF. Vitamin A active metabolite, all-trans retinoic acid, induces spinal cord sensitization. II. Effects after intrathecal administration. Br J Pharmacol. 2006;149(1):65-72. (Pubitemid 44299069)
15. Romero-Sandoval EA, Alique M, Moreno-Manzano V, Molina C, Lucio FJ, Herrero JF. The oral administration of retinoic acid enhances nociceptive withdrawal reflexes in rats with soft-tissue inflammation. Inflamm Res. 2004;53(7):297-303. (Pubitemid 38969360)
16. Lumpkin EA, Caterina MJ. Mechanisms of sensory transduction in the skin. Nature. 2007;445(7130):858-865.
17. Ballantyne B. Peripheral chemosensory irritation: fundamentals, investigation and applied considerations. In: General, Applied and Systems Toxicology. Hoboken, New Jersey, USA: John Wiley & Sons; 2009.
18. Steinhoff M, Stander S, Seeliger S, Ansel JC, Schmelz M, Luger T. Modern aspects of cutaneous neurogenic inflammation. Arch Dermatol. 2003;139(11):1479-1488. (Pubitemid 37433137)
19. Zegarska B, Lelinska A, Tyrakowski T. Clinical and experimental aspects of cutaneous neurogenic inflammation. Pharmacol Rep. 2006;58(1):13-21.
20. Clapham DE. TRP channels as cellular sensors. Nature. 2003;426(6966):517-524. (Pubitemid 37522633)
21. Patapoutian A, Tate S, Woolf CJ. Transient receptor potential channels: targeting pain at the source. Nat Rev Drug Discov. 2009;8(1):55-68.
22. Hardie RC. TRP channels and lipids: from Drosophila to mammalian physiology. J Physiol. 2007;578(pt 1):9-24. (Pubitemid 44971106)
23. Nilius B, Mahieu F, Karashima Y, Voets T. Regulation of TRP channels: a voltage-lipid connection. Biochem Soc Trans. 2007;35(pt 1):105-108.
24. Hu H, Bandell M, Petrus MJ, Zhu MX, Patapoutian A. Zinc activates damage-sensing TRPA1 ion channels. Nat Chem Biol. 2009;5(3):183-190.
25. Nieto-Posadas A, et al. Lysophosphatidic acid directly activates TRPV1 through a C-terminal binding site. Nat Chem Biol. 2012;8(1):78-85.
26. Park KA, Vasko MR. Lipid mediators of sensitivity in sensory neurons. Trends Pharmacol Sci. 2005;26(11):571-577. (Pubitemid 41505225)
27. Villablanca JG, et al. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group. Clin Cancer Res. 2011;17(21):6858-6866.
28. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389(6653):816-824. (Pubitemid 27462969)
29. Touska F, Marsakova L, Teisinger J, Vlachova V. A "cute" desensitization of TRPV1. Curr Pharm Biotechnol. 2011;12(1):122-129.
30. Meggs WJ. Neurogenic inflammation and sensitivity to environmental chemicals. Environ Health Perspect. 1993;101(3):234-238.
31. Lynn B. Neurogenic inflammation caused by cutaneous polymodal receptors. Prog Brain Res. 1996;113:361-368. (Pubitemid 27047061)
32. Planells-Cases R, Garcia-Sanz N, Morenilla-Palao C, Ferrer-Montiel A. Functional aspects and mechanisms of TRPV1 involvement in neurogenic inflammation that leads to thermal hyperalgesia. Pflugers Arch. 2005;451(1):151-159. (Pubitemid 41424918)
33. Rigoni M, et al. Neurogenic responses mediated by vanilloid receptor-1 (TRPV1) are blocked by the high affinity antagonist, iodo-resiniferatoxin. Br J Pharmacol. 2003;138(5):977-985. (Pubitemid 36390655)
34. Trevisani M, et al. 4-Hydroxynonenal, an endogenous aldehyde, causes pain and neurogenic inflammation through activation of the irritant receptor TRPA1. Proc Natl Acad Sci U S A. 2007;104(33):13519-13524. (Pubitemid 47293977)
35. Engel MA, et al. TRPA1 and substance P mediate colitis in mice. Gastroenterology. 2011;141(4):1346-1358.
36. Ward SM, Bayguinov J, Won KJ, Grundy D, Berthoud HR. Distribution of the vanilloid receptor (VR1) in the gastrointestinal tract. J Comp Neurol. 2003;465(1):121-135. (Pubitemid 37075684)
37. Christianson JA, McIlwrath SL, Koerber HR, Davis BM. Transient receptor potential vanilloid 1-immunopositive neurons in the mouse are more prevalent within colon afferents compared to skin and muscle afferents. Neuroscience. 2006;140(1):247-257. (Pubitemid 44269019)
38. Ahluwalia J, Urban L, Bevan S, Nagy I. Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Eur J Neurosci. 2003;17(12):2611-2618. (Pubitemid 36819286)
39. Zygmunt PM, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 1999;400(6743):452-457. (Pubitemid 29361798)
40. Newbold P, Brain SD. The modulation of inflammatory oedema by calcitonin gene-related peptide. Br J Pharmacol. 1993;108(3):705-710. (Pubitemid 23067940)
41. Caterina MJ, et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science. 2000;288(5464):306-313. (Pubitemid 30226186)
42. Davis JB, et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature. 2000;405(6783):183-187. (Pubitemid 30313536)
43. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 1988;32(1):77-88.
44. Kanai Y, Nakazato E, Fujiuchi A, Hara T, Imai A. Involvement of an increased spinal TRPV1 sensitization through its up-regulation in mechanical allodynia of CCI rats. Neuropharmacology. 2005;49(7):977-984. (Pubitemid 41503297)
45. McGaraughty S, et al. Contributions of central and peripheral TRPV1 receptors to mechanically evoked and spontaneous firing of spinal neurons in inflamed rats. J Neurophysiol. 2008;100(6):3158-3166.
46. Hillery CA, et al. Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease. Blood. 2011;118(12):3376-3383.
47. Gavva NR, et al. AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b] [1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. J Pharmacol Exp Ther. 2005;313(1):474-484. (Pubitemid 40411374)
48. Standeven AM, Teng M, Chandraratna RA. Lack of involvement of retinoic acid receptor alpha in retinoid-induced skin irritation in hairless mice. Toxicol Lett. 1997;92(3):231-240. (Pubitemid 27400114)
49. Latorre R, Brauchi S, Orta G, Zaelzer C, Vargas G. ThermoTRP channels as modular proteins with allosteric gating. Cell Calcium. 2007;42(4-5):427-438. (Pubitemid 47264003)
50. Jordt SE, Tominaga M, Julius D. Acid potentiation of the capsaicin receptor determined by a key extracellular site. Proc Natl Acad Sci U S A. 2000;97(14):8134-8139. (Pubitemid 30460785)
51. Ahern GP, Brooks IM, Miyares RL, Wang XB. Extracellular cations sensitize and gate capsaicin receptor TRPV1 modulating pain signaling. J Neurosci. 2005;25(21):5109-5116. (Pubitemid 40726964)
52. Grandl J, et al. Temperature-induced opening of TRPV1 ion channel is stabilized by the pore domain. Nat Neurosci. 2010;13(6):708-714.
53. Jordt SE, Julius D. Molecular basis for species-specific sensitivity to "hot" chili peppers. Cell. 2002;108(3):421-430. (Pubitemid 34178405)
54. Jara-Oseguera A, Simon SA, Rosenbaum T. TRPV1: on the road to pain relief. Curr Mol Pharmacol. 2008;1(3):255-269.
55. Han SK, Simon MI. Intracellular signaling and the origins of the sensations of itch and pain. Sci Signal. 2011;4(185):pe38.
56. Toth BI, et al. Transient receptor potential vanilloid-1 signaling as a regulator of human sebocyte biology. J Invest Dermatol. 2009;129(2):329-339.
57. Lee YM, Kim YK, Chung JH. Increased expression of TRPV1 channel in intrinsically aged and photoaged human skin in vivo. Exp Dermatol. 2009;18(5):431-436.
58. Stander S, Schneider SW, Weishaupt C, Luger TA, Misery L. Putative neuronal mechanisms of sensitive skin. Exp Dermatol. 2009;18(5):417-423.
59. Kawaguchi R, et al. A membrane receptor for retinol binding protein mediates cellular uptake of vitamin A. Science. 2007;315(5813):820-825.
60. Werner EA, Deluca HF. Retinoic acid is detected at relatively high levels in the CNS of adult rats. Am J Physiol Endocrinol Metab. 2002;282(3):E672-E678. (Pubitemid 34654785)
61. Lopez-Vales R, et al. Fenretinide promotes functional recovery and tissue protection after spinal cord contusion injury in mice. J Neurosci. 2010;30(9):3220-3226.
62. Hernandez-Pedro N, et al. All-trans retinoic acid induces nerve regeneration and increases serum and nerve contents of neural growth factor in experimental diabetic neuropathy. Transl Res. 2008;152(1):31-37.
63. Puttagunta R, Di Giovanni S. Retinoic acid signaling in axonal regeneration. Front Mol Neurosci. 2011;4:59.
64. Zhelyaznik N, Schrage K, McCaffery P, Mey J. Activation of retinoic acid signalling after sciatic nerve injury: up-regulation of cellular retinoid binding proteins. Eur J Neurosci. 2003;18(5):1033-1040. (Pubitemid 37115025)
65. Pecze L, et al. Human keratinocytes are vanilloid resistant. PLoS One. 2008;3(10):e3419.
66. El Andaloussi-Lilja J, Lundqvist J, Forsby A. TRPV1 expression and activity during retinoic acid-induced neuronal differentiation. Neurochem Int. 2009;55(8):768-774.
67. Devaux Y, et al. Retinoic acid and lipopolysaccharide act synergistically to increase prostanoid concentrations in rats in vivo. J Nutr. 2001;131(10):2628-2635. (Pubitemid 32947787)
68. Li Y, Hashimoto Y, Agadir A, Kagechika H, Zhang X. Identification of a novel class of retinoic acid receptor beta-selective retinoid antagonists and their inhibitory effects on AP-1 activity and retinoic acid-induced apoptosis in human breast cancer cells. J Biol Chem. 1999;274(22):15360-15366.
69. Agarwal C, Chandraratna RA, Johnson AT, Rorke EA, Eckert RL. AGN193109 is a highly effective antagonist of retinoid action in human ectocervical epithelial cells. J Biol Chem. 1996;271(21):12209-12212. (Pubitemid 26163335)
70. Touska F, Marsakova L, Teisinger J, Vlachova V. A "cute" desensitization of TRPV1. Curr Pharm Biotechnol. 2011;12(1):122-129.
71. Gavva NR, et al. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain. 2008;136(1-2):202-210.
72. Wong GY, Gavva NR. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks. Brain Res Rev. 2009;60(1):267-277.
73. Moran MM, McAlexander MA, Bíró T, Szallasi A. Transient receptor potential channels as therapeutic targets. Nat Rev Drug Discov. 2011;10(8):601-620.
74. Engel MA, et al. The proximodistal aggravation of colitis depends on substance P released from TRPV1-expressing sensory neurons. J Gastroenterol. 2012;47(3):256-265.
75. Luo J, Zhu Y, Zhu MX, Hu H. Cell-based calcium assay for medium to high throughput screening of TRP channel functions using FlexStation 3. J Vis Exp. 2011;(54).pii:3149.
76. Petrus M, et al. A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition. Mol Pain. 2007;3:40.
77. Bedi SS, et al. Chronic spontaneous activity generated in the somata of primary nociceptors is associated with pain-related behavior after spinal cord injury. J Neurosci. 2010;30(44):14870-14882.